These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 606413)
1. The effect of dialysate calcium concentration on 1alpha-hydroxyvitamin D3 on skeletal calcium loss and hyperparathyroidism in haemodialysis patients. Winney RJ; Tothill P; Robson JS; Abbot SR; Lidgard GP; Cameron EH; Smith MA; Macpherson HN; Strong JA Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():151s-158s. PubMed ID: 606413 [TBL] [Abstract][Full Text] [Related]
2. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy. Junor BJ; Catto GR Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411 [TBL] [Abstract][Full Text] [Related]
3. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2. Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R Nephron; 1992; 60(2):154-63. PubMed ID: 1552999 [TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
5. Measurement of whole body calcium in chronic renal failure: effects of 1alpha-hydroxyvitamin D3 and parathyroidectomy. Naik RB; Dabek JT; Heynen G; James HM; Kanis JA; Robertson PW; Robinson BH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():139s-145s. PubMed ID: 564247 [TBL] [Abstract][Full Text] [Related]
6. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B Nephron; 1995; 71(3):254-83. PubMed ID: 8569975 [TBL] [Abstract][Full Text] [Related]
7. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients. Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265 [TBL] [Abstract][Full Text] [Related]
8. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone. Bro S; Brandi L; Olgaard K Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216 [TBL] [Abstract][Full Text] [Related]
9. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency. Pietrek J; Kokot F; Kuska J Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol]. Switalski M; Kuriga M; Wańkowicz Z Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090 [TBL] [Abstract][Full Text] [Related]
11. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium. Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904 [TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K Nephron; 1989; 53(3):194-200. PubMed ID: 2797340 [TBL] [Abstract][Full Text] [Related]
13. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174 [TBL] [Abstract][Full Text] [Related]
14. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K Nephron; 1996; 74(1):89-103. PubMed ID: 8883025 [TBL] [Abstract][Full Text] [Related]
15. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients. Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167 [TBL] [Abstract][Full Text] [Related]
16. Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure. Nielsen HE; Christensen MS; Melsen F; Rømer FK; Hansen HE Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():67s-72s. PubMed ID: 606427 [TBL] [Abstract][Full Text] [Related]
17. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Memmos DE; Eastwood JB; Talner LB; Gower PE; Curtis JR; Phillips ME; Carter GD; Alaghband-Zadeh J; Roberts AP; de Wardener HE Br Med J (Clin Res Ed); 1981 Jun; 282(6280):1919-24. PubMed ID: 6786673 [TBL] [Abstract][Full Text] [Related]
18. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease. Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424 [TBL] [Abstract][Full Text] [Related]
19. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3. Peacock M; Aaron JE; Walker GS; Davison AM Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428 [No Abstract] [Full Text] [Related]
20. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease. Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]